639 related articles for article (PubMed ID: 34471285)
1. Functional HPV-specific PD-1
Eberhardt CS; Kissick HT; Patel MR; Cardenas MA; Prokhnevska N; Obeng RC; Nasti TH; Griffith CC; Im SJ; Wang X; Shin DM; Carrington M; Chen ZG; Sidney J; Sette A; Saba NF; Wieland A; Ahmed R
Nature; 2021 Sep; 597(7875):279-284. PubMed ID: 34471285
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.
Aggarwal C; Cohen RB; Morrow MP; Kraynyak KA; Sylvester AJ; Knoblock DM; Bauml JM; Weinstein GS; Lin A; Boyer J; Sakata L; Tan S; Anton A; Dickerson K; Mangrolia D; Vang R; Dallas M; Oyola S; Duff S; Esser M; Kumar R; Weiner D; Csiki I; Bagarazzi ML
Clin Cancer Res; 2019 Jan; 25(1):110-124. PubMed ID: 30242022
[TBL] [Abstract][Full Text] [Related]
3. Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer.
Wu A; Zeng Q; Kang TH; Peng S; Roosinovich E; Pai SI; Hung CF
Gene Ther; 2011 Mar; 18(3):304-12. PubMed ID: 20981112
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model.
Ishida E; Lee J; Campbell JS; Chakravarty PD; Katori Y; Ogawa T; Johnson L; Mukhopadhyay A; Faquin WC; Lin DT; Wirth LJ; Pierce RH; Pai SI
Cancer Immunol Immunother; 2019 Aug; 68(8):1273-1286. PubMed ID: 31243491
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.
Smalley Rumfield C; Pellom ST; Morillon Ii YM; Schlom J; Jochems C
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612
[TBL] [Abstract][Full Text] [Related]
6. Human Papilloma Virus Specific Immunogenicity and Dysfunction of CD8
Krishna S; Ulrich P; Wilson E; Parikh F; Narang P; Yang S; Read AK; Kim-Schulze S; Park JG; Posner M; Wilson Sayres MA; Sikora A; Anderson KS
Cancer Res; 2018 Nov; 78(21):6159-6170. PubMed ID: 30154146
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
[TBL] [Abstract][Full Text] [Related]
8. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
9. CXCR6 deficiency impairs cancer vaccine efficacy and CD8
Karaki S; Blanc C; Tran T; Galy-Fauroux I; Mougel A; Dransart E; Anson M; Tanchot C; Paolini L; Gruel N; Gibault L; Lepimpec-Barhes F; Fabre E; Benhamouda N; Badoual C; Damotte D; Donnadieu E; Kobold S; Mami-Chouaib F; Golub R; Johannes L; Tartour E
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33692218
[TBL] [Abstract][Full Text] [Related]
10. PD-1 Status in CD8
Kansy BA; Concha-Benavente F; Srivastava RM; Jie HB; Shayan G; Lei Y; Moskovitz J; Moy J; Li J; Brandau S; Lang S; Schmitt NC; Freeman GJ; Gooding WE; Clump DA; Ferris RL
Cancer Res; 2017 Nov; 77(22):6353-6364. PubMed ID: 28904066
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral Tcf1
Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
[TBL] [Abstract][Full Text] [Related]
12. Defining HPV-specific B cell responses in patients with head and neck cancer.
Wieland A; Patel MR; Cardenas MA; Eberhardt CS; Hudson WH; Obeng RC; Griffith CC; Wang X; Chen ZG; Kissick HT; Saba NF; Ahmed R
Nature; 2021 Sep; 597(7875):274-278. PubMed ID: 33208941
[TBL] [Abstract][Full Text] [Related]
13. HPV Epitope Processing Differences Correlate with ERAP1 Allotype and Extent of CD8
Reeves E; Wood O; Ottensmeier CH; King EV; Thomas GJ; Elliott T; James E
Cancer Immunol Res; 2019 Jul; 7(7):1202-1213. PubMed ID: 31151965
[TBL] [Abstract][Full Text] [Related]
14. PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model.
Peng S; Tan M; Li YD; Cheng MA; Farmer E; Ferrall L; Gaillard S; Roden RBS; Hung CF; Wu TC
Cancer Immunol Immunother; 2021 Apr; 70(4):1049-1062. PubMed ID: 33108473
[TBL] [Abstract][Full Text] [Related]
15. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.
Badoual C; Hans S; Merillon N; Van Ryswick C; Ravel P; Benhamouda N; Levionnois E; Nizard M; Si-Mohamed A; Besnier N; Gey A; Rotem-Yehudar R; Pere H; Tran T; Guerin CL; Chauvat A; Dransart E; Alanio C; Albert S; Barry B; Sandoval F; Quintin-Colonna F; Bruneval P; Fridman WH; Lemoine FM; Oudard S; Johannes L; Olive D; Brasnu D; Tartour E
Cancer Res; 2013 Jan; 73(1):128-38. PubMed ID: 23135914
[TBL] [Abstract][Full Text] [Related]
16. Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1.
Garcia-Bates TM; Kim E; Concha-Benavente F; Trivedi S; Mailliard RB; Gambotto A; Ferris RL
J Immunol; 2016 Mar; 196(6):2870-8. PubMed ID: 26851223
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
[TBL] [Abstract][Full Text] [Related]
18. Validation of Human Papillomavirus as a Favourable Prognostic Marker and Analysis of CD8
Sivars L; Landin D; Grün N; Vlastos A; Marklund L; Nordemar S; Ramqvist T; Munck-Wikland E; Näsman A; Dalianis T
Anticancer Res; 2017 Feb; 37(2):665-673. PubMed ID: 28179315
[TBL] [Abstract][Full Text] [Related]
19. CD8
Masterson L; Lechner M; Loewenbein S; Mohammed H; Davies-Husband C; Fenton T; Sudhoff H; Jani P; Goon P; Sterling J
Eur J Cancer; 2016 Nov; 67():141-151. PubMed ID: 27669501
[TBL] [Abstract][Full Text] [Related]
20. An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer.
de Vos van Steenwijk PJ; Heusinkveld M; Ramwadhdoebe TH; Löwik MJ; van der Hulst JM; Goedemans R; Piersma SJ; Kenter GG; van der Burg SH
Cancer Res; 2010 Apr; 70(7):2707-17. PubMed ID: 20233872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
